Page 10 - Read Online
P. 10

59         Role of the contrast-enhanced ultrasoud in the diagnosis of HCC in cirrhotic liver
                            Francesco Loria, Antonello Parlati, Giuseppe Loria, Luciano Frosina, Giuseppe Crea, Salvatore Basile,
                            Caterina Alessio, Giuseppe Di Leo, Adele De Caridi, Vittorio Maschio, Nicola Zizzi, Orazio
                            Trapuzzano, Salvatore Giuseppe Galea
                            Hepatoma Res 2018;4:59  http://dx.doi.org/10.20517/2394-5079.2018.75


               60         Liver transplantation for hepatocellular carcinoma - non-cancer factors and implications for
                            improving outcome beyond standard tumor criteria
                            Arno Kornberg, Martina Schernhammer
                            Hepatoma Res 2018;4:60  http://dx.doi.org/10.20517/2394-5079.2018.86


               61         Novel diagnosis and therapy for hepatoma targeting HBV-related carcinogenesis through
                            alternative splicing of FIR (PUF60)/FIRΔexon2
                            Kazuyuki Matsushita, Tyuji Hoshino
                            Hepatoma Res 2018;4:61  http://dx.doi.org/10.20517/2394-5079.2018.81


               62         Quantitative hepatitis B surface antigen in predicting recurrence of hepatitis B-related
                            hepatocellular carcinoma after liver transplantation
                            James Fung, Danny Ka-Ho Wong, Yasuhito Tanaka, Regina Lo, Tiffany Wong, Kenneth Siu-Ho Chok,
                            Albert Chi-Yan Chan, Tan-To Cheung, Wing-Chiu Dai, Kelvin Ng, Kevin Ng, Man Kwan, Irene Ng,
                            Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen, Chung-Mau Lo
                            Hepatoma Res 2018;4:62  http://dx.doi.org/10.20517/2394-5079.2018.92


               63         Alpha-fetoprotein as a predictor of hepatocellular carcinoma recurrence following liver
                            transplantation
                            Evangelia M. Fatourou, Abid R. Suddle, Michael A. Heneghan
                            Hepatoma Res 2018;4:63  http://dx.doi.org/10.20517/2394-5079.2018.62


               64         HCV elimination: breaking down the barriers to prison based care
                            Timothy Papaluca, Alexander Thompson
                            Hepatoma Res 2018;4:64  http://dx.doi.org/10.20517/2394-5079.2018.53

               65         New and old biomarkers of hepatocellular carcinoma
                            Georgios Zacharakis, Ahmad Aleid, Khaled K Aldossari
                            Hepatoma Res 2018;4:65  http://dx.doi.org/10.20517/2394-5079.2018.76


               66         Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/
                            steatohepatitis and liver transplantation
                            Eric M. Wu, Linda L. Wong, Brenda Y. Hernandez, Jun-Fang Ji, Wei Jia, Sandi A. Kwee, Sumodh
                            Kalathil
                            Hepatoma Res 2018;4:66  http://dx.doi.org/10.20517/2394-5079.2018.87


               67         Endolymphatic immunotherapy for advanced hepatocellular carcinoma: an update of our
                            experience
                            Marialuisa Lugaresi, Yuval Katz, Riccardo Bertelli, Noa Ruhrman, Lorenza Puviani, Giuseppe
                            Cavallari, Caterina De Vinci, Giancarlo Pizza, Bruno Nardo
                            Hepatoma Res 2018;4:67  http://dx.doi.org/10.20517/2394-5079.2018.88
   5   6   7   8   9   10   11   12   13   14   15